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Abstract: BACKGROUND:: CRS/HIPEC gained acceptance as a treatment for selected patients with
peritoneal metastasis. However, the pathophysiology behind HIPEC is poorly understood, and a variety
of regimens are currently in use. In this study, we describe for the first-time changes in the postopera-
tive systemic inflammatory reaction, highly different among HIPEC treatment protocols. METHODS::
HIPEC was performed with three protocols, different with regard to perfusion times and drugs: (mito-
mycinC/doxorubicin, 90min), (cisplatin, 90min) (oxaliplatin, 30min). Serial blood samples were assessed
for C-reactive protein (CRP), white blood cells (WBC), pancreatic stone protein (PSP) and bacterial
component (16s rDNA). The study was approved by the local ethics committee and registered at clini-
caltirals.gov (NCT02741167). RESULTS:Overall, 140 patients from two European centers were included.
In patients without postoperative complications, a secondary peak of inflammatory parameters, CRP (p
= 0.015) and PSP (p = 0.004) was observed after HIPEC for 90 min with mitomycinC/doxorubicin or
cisplatin but not after 30 min oxaliplatin. In patients after 90 min HIPEC, postoperative serum bacterial
16srDNA level were 2.1 times higher (95% CI 0.646-3.032, p = 0.015) compared to 30 min oxaliplatin.
DISCUSSION: In conclusion, we identified a secondary inflammatory reaction after 90 min HIPEC, either
with mitomycinC/doxorubicin or cisplatin, not observed after short course HIPEC with oxaliplatin. This
protocol dependent physiology of acute phase proteins should be known in the clinical management of
patients after HIPEC.
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CRS  Cytoreductive surgery 
HIPEC  Hyperthermic intraperitoneal chemotherapy 
PCI   Peritoneal cancer index 
CC-Score Completeness of cytoreduction score 
CRC  Colorectal carcinoma 
CRP  C-reactive protein 
PSP  Pancreatic stone protein 



























Background: CRS/HIPEC gained acceptance as a treatment for selected patients with peritoneal 
metastasis. However, the pathophysiology behind HIPEC is poorly understood, and a variety of 
regimens are currently in use. In this study, we describe for the first-time changes in the postoperative 
systemic inflammatory reaction, highly different among HIPEC treatment protocols. 
Methods: HIPEC was performed with three protocols, different with regard to perfusion times and 
drugs: (mitomycinC/doxorubicin, 90min), (cisplatin, 90min) (oxaliplatin, 30min). Serial blood samples 
were assessed for C-reactive protein (CRP), white blood cells (WBC), pancreatic stone protein (PSP) 
and bacterial component (16s rDNA). The study was approved by the local ethics committee and 
registered at clinicaltirals.gov (NCT02741167). 
Results: Overall, 140 patients from two European centers were included. In patients without 
postoperative complications, a secondary peak of inflammatory parameters, CRP (p=0.015) and PSP 
(p=0.004) was observed after HIPEC for 90 minutes with mitomycinC/doxorubicin or cisplatin but not 
after 30 minutes oxaliplatin. In patients after 90 minutes HIPEC, postoperative serum bacterial 
16srDNA level were 2.1 times higher (95% CI 0.646-3.032, p=0.015) compared to 30 minutes 
oxaliplatin. 
Discussion: In conclusion, we identified a secondary inflammatory reaction after 90 minutes HIPEC, 
either with mitomycinC/doxorubicin or cisplatin, not observed after short course HIPEC with oxaliplatin. 
This protocol dependent physiology of acute phase proteins should be known in the clinical 


























Peritoneal metastasis (PM) occurs from many gastrointestinal tumors, e.g. colorectal cancer or 
appendix cancer, and has an inferior prognosis than metastasis to the liver or lungs [1]. Cytoreductive 
surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), together with multimodal 
systemic treatment, has become a valuable option for selected patients [2-4] translating into 
considerable survival benefits [5, 6]. There is good in-vitro data about cytotoxic effects of HIPEC on 
cultured colorectal cancer cells [7], and data in humans show favorable pharmacokinetic effects for 
HIPEC. In contrast, specific effects of HIPEC on patient physiology and the postoperative course are 
poorly explored. In addition, existing HIPEC protocols differ with regard to drugs, temperatures and 
treatment duration. For example, in patients with colorectal PM, distinct HIPEC protocols are currently 
in use. One protocol, initially developed by Sugarbaker et al, is mitomycinC-based, and used for 90 
minutes at 42°C, currently preferred by many US centers [8], while a majority of European centers use 
a shorter protocol for 30 minutes at 43°C which is oxaliplatin-based, and was originally published by 
French groups [9]. So far, no difference regarding overall survival between the two protocols has been 
shown in retrospective studies [10], and the choice for a specific protocol is center dependent. 
Currently, the main argument for the majority of surgeons preferring the French protocol is the shorter 
perfusion time compared to the US protocol. Many other protocols exist, for example with cisplatin, 
which is frequently applied during 90 minutes at 42°C and used for PM from ovarian cancer or 
peritoneal mesothelioma. Cisplatin is an alkylating agent like oxaliplatin, while the perfusion time and 
the applied temperature is similar to the mitomycin C protocol. 
CRS/HIPEC induces complex physiological changes in patients, particularly during the 
operation and in the early postoperative phase [11]. During HIPEC, absorption of chemotherapeutic 
agents may systemically affect WBC counts [12-14]. In addition, local heat exposure and 
chemotherapy can induce direct toxic damage to abdominal organs with so far unknown effects on a 
patient’s physiology [15]. This knowledge about HIPEC is currently not available but may help to 
improve efficacy without increasing risks of HIPEC in the near future. Here, we aimed to assess the 























Material and Methods 
Patients & Ethics 
Patients from two centers (Zurich, Switzerland, and Vienna, Austria) treated with CRS/HIPEC for 
malignant gastrointestinal tumors between 2009 and 2017 were included in this study. Patient data 
were collected retrospectively (n=42) between 2009 and 2015, and within a prospective protocol 
(n=98) between 2015 and 2017. The study protocol was approved by the ethical committee and 
registered at clinicaltirals.gov (NCT02741167). 
Treatment 
Patients were discussed at interdisciplinary tumor boards after exclusion of extra-abdominal tumor 
manifestations by 18FDG-PET/CT or thoracic-abdominal CT. Patients received standard of care pre- 
and postoperative chemotherapy according to tumor entity and international guidelines. Anesthesia 
was conducted with propofol and volatile anesthetics combined with thoracic epidural anesthesia as 
described previously[11]. CRS was performed according to international standards and defined as 
radical (CC-Score 0) if no macroscopic residual tumor was visible [16]. HIPEC for appendix and 
colorectal tumors was performed using peritoneal dialysis solution for mitomycinC (30mg/m
2
 body 
surface area, BSA according to the Mosteller formula) in combination with doxorubicin (15mg/m
2
 BSA) 
for 42°C for 90 minutes, or oxaliplatin (300-400mgm
2
 BSA) as single agent at 43°C for 30 minutes. 
The type of protocol used for appendix or colon cancer was changed in both centers in 2016 from the 
mitomycinC/doxorubicin protocol to the oxaliplatin protocol, which was then consistently used for these 
primary tumors. Patients with mesothelioma or ovarian cancer were treated with cisplatin-based 
HIPEC (75mg/m
2
 BSA) for 90 minutes at 42°C.  
Clinical parameters 
Patients after CRS/HIPEC were visited daily by the operating surgeon according to standard clinical 
routine. In case of clinical symptoms or signs of infection, blood, urine and central catheters tips 
(jugular or subclavian) were taken for cultures. Imaging studies, usually an abdominal CT, were 























according to the Clavien-Dindo classification[17], while infectious complications were defined 
according to the Center for Disease Control and Prevention (CDC) definitions [18]. 
Serum probes  
C-reactive protein (CRP), white blood cell (WBC) counts, pancreatic stone protein (PSP) were 
measured in blood samples by the clinical laboratory service on a daily routine basis prior to surgery 
and for the 14 consecutive postoperative days[19]. PSP was measured from frozen serum samples 
with enzyme-linked immunosorbent assays (ELISA) as previously reported.[20] DNA was extracted 
from fresh frozen serum samples using the DNeasy Blood and Tissue Kit (Qiagen). Quantitative 
polymerase chain reaction (qPCR) with TaqMan (Pa04230899_s1) was performed to assess bacterial 
components (16srDNA)[21]. 
Statistical analysis  
Continuous variables were compared with the student t-test, the Mann–Whitney U or the 
Wilcoxon test, where appropriate. Fischer’s Exact tests was used to compare differences among 
proportions derived from categorical data. Normally distributed data are shown as mean +/- SD, non-
normal variables as median and interquartile range (IQR). Missing values in the dataset were 
excluded. All p values were two-sided and considered statistically significant if p≤0.05. Statistical 

























Demographic data  
Overall, n=140 patients (n= 91 from Zurich, n=49 from Vienna) were included in the analysis. 
Patient characteristics are summarized in Table 1. Patients after HIPEC with oxaliplatin (n=44) were 
compared to patients after HIPEC with mitomycinC/doxorubicin (n=53) or cisplatin-based protocol 
(n=43). The mitomycinC/doxorubicin protocol and the oxaliplatin protocol were applied to similar types 
of primary tumors. Cisplatin-based HIPEC was primarily performed for mesothelioma or ovarian 
cancer. Detailed patient characteristics and differences between the treatment groups are summarized 
in supplementary table 1.  
 
Prolonged HIPEC with mitomycinC/doxorubicin or cisplatin induces an unspecific 
secondary C-reactive protein peak  
We expected to find a similar level of postoperative inflammation among protocols in patients 
without postoperative complications, However, in patients after CRS/HIPEC without any complication, 
we identified an unspecific secondary increase of CRP after HIPEC with mitomycinC/doxorubicin or 
cisplatin at 42°C for 90 minutes. This CRP increase was significant for mitomycinC/doxorubicin 
(p=0.015), and cisplatin (p=0.026) (Figure 1A, 1B). This effect was not observed in patients 
undergoing 30 minutes HIPEC with oxaliplatin at 43°C, where CRP levels gradually declined and 
returned to almost normal reference values within the first 14 postoperative days (Figure 1C).  
 
Pancreatic stone protein confirms the presence of an inflammatory trigger 
Pancreatic stone protein (PSP) is an acute phase protein produced in the pancreas after a 
septic stimulus[22]. Serum levels of pancreatic stone protein (PSP) dramatically increased in patients 
after HIPEC with the mitomycinC/doxorubicin protocol (p=0.004) and cisplatin-based HIPEC (p=0.031) 
between day 2 and 6, in contrast to patients after HIPEC with the oxaliplatin protocol, where no 
increase was observed (Figure 2A - C). The secondary rise of CRP (generated in the liver) and PSP 

























Bacterial components identified as a potential triggering source of inflammation 
To explore the trigger of this secondary inflammatory reaction, we analyzed fresh frozen serum 
samples for the presence of bacterial components. Bacterial 16srDNA levels from patients with septic 
complications served as positive controls. The relative amount of bacterial DNA (16s rDNA) was 2.1 
times higher (95% CI 0.646-3.032, p=0.015) in patients after HIPEC with the mitomycinC/doxorubicin 
protocol compared to the oxaliplatin protocol (Figure 3). In line with this finding, the relative bacterial 
components were 2.5 times higher (95% CI 0.567-4.85, p=0.015) after the treatment with the cisplatin-
based protocol compared to the oxaliplatin protocol, suggesting prolonged perfusion times as the 
triggering factor.  
 
White blood cells (WBC) increases after platin-based HIPEC 
Median WBC counts remained within a normal range of 5-10 G/l among all three HIPEC 
regimens. However, a secondary WBC increase could be observed between day 4 and 7 after platin-
based HIPEC (Figure 4B, 4C) treatment in patients without any complications. WBC did not change 
after mitomycinC/doxorubicin HIPEC treatment, even though these patient population showed a 

























Our study identifies novel findings related to the pathophysiology of acute phase proteins in 
patients after HIPEC. For the first time, we describe a secondary inflammatory reaction, associated to 
the presence of bacterial components in the systemic circulation after CRS/HIPEC. The data provides 
insight into the human pathophysiology after HIPEC which is necessary to understand the physiology 
and manage the postoperative course. In the future, it will help to direct future modifications of the 
HIPEC procedure. 
 
Our finding of an unspecific secondary inflammation phase after HIPEC was unexpected. First, 
we thought about an influence of major surgery or the postoperative management, but a comparison 
with open colorectal and open gastroesophageal surgery (data not shown) highlighted an impact of 
HIPEC itself. To our surprise this secondary inflammatory peak was also not observed after HIPEC 
with oxaliplatin. Since these patients shared surgical characteristics of patients after HIPEC with 
mitomycin/doxorubicin, we could exclude a potential role of the cytoreduction part or the perioperative 
management (e.g. parenteral nutrition, epidural anesthesia, intraabdominal drainage, central vein 
lines) as an additional source of inflammation. In our study, patients after 90 minutes HIPEC with 
mitomycinC/doxorubicin or cisplatin showed a secondary CRP peak, simultaneously with a marked 
elevation of PSP, and the presence of bacterial ribosomal DNA in the patient serum. Although difficult 
to prove in the human setting, this finding is suggestive of intestinal bacterial translocation. Support for 
this hypothesis comes from rat experiments, where increased bacterial components were identified in 
mesenterial lymph nodes on the third postoperative day after HIPEC [23]. Whether translocation 
occurred because of direct damage to the intestinal mucosa or due to decreased host defense 
remains so far unclear. To address the question whether different drugs or longer perfusion times are 
responsible, we compared a cisplatin-based protocol with the mitomycinC/doxorubicin and oxaliplatin 
protocol. Cisplatin is a compound similar to oxaliplatin but is usually performed at conditions similar to 
the mitomycinC/doxorubicin protocol (42°C, 90 minutes). Finally, after prolonged perfusion with 
cisplatin, we also observed a secondary inflammatory peak, indicating that prolonged exposure time to 
HIPEC might be the critical factor. This observation is similar to a report from Spain, where this 
observation was not reported but the data and figures indicate the same kinetics for CRP after a 
























A justified question is the clinical relevance of our finding. Indeed, we did not observe a clinically 
relevant overall difference regarding postoperative complications between the different protocols. 
However, the ratio of deep organ space (CDC definition) infections was higher after HIPEC with 
mitomycinC/doxorucicin compared to oxaliplatin (30% vs 11%, p=0.028), and two patients in this 
protocol group had postoperative peritonitis without an underlying digestive fistula, and observation 
also made by others [25]. This may indicate that, although a rare event, bacterial translocation may 
contribute to adverse postoperative outcomes. Another question is whether HIPEC with oxaliplatin is 
still relevant after the results of PRODIGE7, since most centers may have changed to other protocols. 
Indeed, the goal of the present study is not to show a benefit of one over another protocol. Our data 
just highlights that protocol parameters, particularly temperature and duration, may significantly impact 
on the pathophysiology of our patients.    
There is, however, another clinical value of these findings. When we initialized the study, we did 
not know about a potential increase in acute phase proteins in absence of complications after 
prolonged perfusion. Consequently, our patients regularly underwent a complex postoperative work-up 
including CT scans, and sometimes surgical reexploration, without revealing any infectious focus. This 
finding urged us to investigate the pathophysiology behind the secondary increase and we started 
measuring markers such as PSP and 16sDNA. Our findings finally highlight the complexity of HIPEC 
and underline the need for a dedicated and specialized team, not only for the procedure itself but also 
in the postoperative management and the interpretation of the clinical status of a patient after 
CRS/HIPEC. Based on our data, we learned that, while a secondary inflammatory reaction can occur 
after prolonged (90 minutes) HIPEC protocols, it was almost never observed after a short, 30 minutes 
protocol.  
CRS/HIPEC treatment improves survival of patients with peritoneal metastasis. However, a 
majority of patients still has recurrent disease within the first two years [26], and future improvements 
of HIPEC are therefore needed. Today, parameters of HIPEC including drugs, perfusion time and 
temperatures are determined empirically, resulting in a huge variation, and major difficulty to compare 
and identify the role of a specific component. In addition, data from animal experiments may not be 
transferable to the human situation. A better understanding of molecular mechanisms, and the human 
pathophysiology of HIPEC is therefore required to intensify and improve existing protocols without 























times of HIPEC should include a monitoring of acute phase proteins, and probably also parameters to 
exclude increased intestinal translocation.  
Another open question is the long-term impact of systemic inflammation after CRS/HIPEC. The 
role of postoperative inflammation and infection on patient survival is controversially discussed in the 
literature, and there is data showing a negative impact on patient outcomes, while other studies show 
no impact on survival [27, 28]. The relevance of our present finding, inflammation in patients without 
complications, regarding patient survival is yet unclear, and would open another door to a molecular 
understanding of HIPEC.  
 
An interesting finding in our study is the kinetics of WBC during the postoperative course of patients 
without a complication. Although, WBC values remained within normal range, we observed changes 
after platin-based HIPEC. Expecting a secondary increase after prolonged HIPEC treatment, we only 
detected an increase in patients after cisplatin-based HIPEC, which suggests a myelodepressive 
effect of mitomycinC/doxorubicin[29]. WBC also increased after oxaliplatin-based HIPEC, even though 
CRP values decreased in a linear manner almost to normal, indicating that a minimal bacterial 
translocation probably also occurs after oxaliplatin-based HIPEC, indicated also by the small quantity 
of bacterial components in the systemic circulation. Regarding the diagnostic workup of patients after 
CRS/HIPEC we would like to highlight a study published in 2016 which assessed the role of 
procalcitonin in the early postoperative phase after CRS/HIPEC. This study concluded that 
procalcitonin may improve the diagnosis of postoperative infection, but needs careful interpretation 
within the clinical context, similar to CRP and white-cell counts [30].    
 
We would like to acknowledge the limitations of our study. The cohort of patients is 
heterogeneous regarding the type of primary tumors. However, treatment associated surgical factors 
are comparable among the three groups which will limit this bias. Finally, we acknowledge that the 
observed association of bacterial components in the bloodstream to systemic inflammation is not a 
mechanistic proof of intestinal translocation. This hypothesis is difficult to investigate and proof in 
humans, and animal experiments may finally be required. Overall, in the majority of patients, this effect 
did not result in a more complicated course. However, it indicates a critical mechanistic step in the 
pathophysiology of HIPEC and may explain the rare finding of peritonitis without a cause, sometimes 
























In conclusion, we identified novel aspects in physiologic changes after CRS/HIPEC, a 
secondary inflammatory reaction in patients after 90 minutes perfusion with HIPEC, associated to 
bacterial components in the systemic circulation. These protocol-specific effects after HIPEC should 
be known to physicians dedicated to the treatment of peritoneal surface malignancies for a better 
understanding of a patient’s physiology. In future, they may help to direct the next evolution of 
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Figure 1: Kinetics of CRP during an uncomplicated course 
Figure 1A: Kinetics of C-reactive protein (CRP) levels in patients without postoperative complications 
(n=107) showing a significant secondary CRP increase after HIPEC with mitomycinC/doxorubicin 
(P=0.015, n=34) between day 5 and day 8. Figure 1B: CRP in patients without complications (n=38) 
after HIPEC with cisplatin showing a secondary CRP increase (P=0.026) between day 6 and 10. 
Figure 1C: Patients treated with oxaliplatin (n=35) present a linear decline of the CRP. Data are shown 
as median and IQR. 
 
Figure 2: PSP confirms an ongoing inflammatory process  
Figure 2A: Postoperative pancreatic stone protein (PSP) in patients without postoperative 
complications after HIPEC with mitomycinC/doxorubicin (n=34). There is a significant PSP increase in 
patients between day 2 and 6 (P=0.004). Figure 2B: Patients after cisplatin – based HIPEC show a a 
significant PSP increase (P=0.031) between day 2 and 6. Figure 1C: No increase of PSP can be 
observed within the first postoperative week after HIPEC with oxaliplatin. Data are shown as median 
and IQR. 
 
Figure 3: Bacterial components associated to the inflammatory response  
Relative changes of bacterial 16srDNA during the postoperative course in patients after uncomplicated 
CRS/HIPEC. Patients after HIPEC with mitomycinC/doxorubicin (P=0.015) or cisplatin (P=0.015) have 
a significantly higher load of bacterial ribosomal DNA (16s rDNA) in their circulation compared to 
patients after HIPEC with oxaliplatin. Septic patients served as a positive control group. Data are 
shown as median and IQR.  
 
Figure 4: Kinetics of WBC during an uncomplicated course 
Figure 4A: Kinetics of white blood cells (WBC) levels in patients without infectious complications after 
CRS/HIPEC (n=107). After an initial increase, WBC decrease and remain in normal range after 
mitomcycinC/doxorubicin HIPEC (n=34). Figure 4B-4C: There is a significant secondary WBC 
increase in patients after platin-based HIPEC (n=38, cisplatin-based, p=0.011, n=35, oxaliplatin-

























Age 56 (47 – 64) 
Sex (male/female) 86 (61.4%) 
54 (38.6%) 
Primary tumor  
Colorectal 54 (38.6%) 
Appendix tumors 35 (25%) 
Mesothelioma 10 (7.1%) 
Others 41 (29.3%) 
PCI 6 (3 – 14) 
Operation time (min) 360 (291.25-449.5) 
Anastomosis (number) 1 (0 – 1) 
ICU stay (days) 1 (1-2.75) 
Hospital stay (days) 15 (12-20.75) 
Complications   
none 85 (60.7%) 
Major complications 
(Clavien-Dindo ≥ IIIb) 
9 (6.4%) 
Mortality (Clavien-Dindo Grade V) 1 (0.7%) 
 

































































mitomycinC/doxorubicin (90min) cisplatin-based (90min) oxaliplatin (30min) 
p=0.015 p=0.026
1A 1B 1C
Figure 1: Kinetics of CRP during an uncomplicated course
Figure 1A: Kinetics of C-reactive protein (CRP) levels in patients without postoperative complications (n=107) showing a significant secondary 
CRP increase after HIPEC with mitomycinC/doxorubicin (P=0.015, n=34) between day 5 and day 8. Figure 1B: CRP in patients without 
complications (n=38) after HIPEC with cisplatin showing a secondary CRP increase (P=0.026) between day 6 and 10. Figure 1C: Patients 

































US protocol (90 min)













Cisplatin-based protocol (90 min)

















mitomycinC/doxorubicin (90min) oxaliplatin (30min) 
Figure 2: PSP confirms an ongoing inflammatory process 
Figure 2A: Postoperative pancreatic stone protein (PSP) in patients without postoperative complications after HIPEC with 
mitomycinC/doxorubicin (n=34). There is a significant PSP increase in patients between day 2 and 6 (P=0.004). Figure 2B: Patients after
cisplatin – based HIPEC show a a significant PSP increase (P=0.031) between day 2 and 6. Figure 1C: No increase of PSP can be observed 
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Figure 3: Bacterial components associated to the inflammatory response 
Relative changes of bacterial 16srDNA during the postoperative course in patients 
after uncomplicated CRS/HIPEC. Septic patients served as a positive control group. 
Patients after mitomycinC/doxorubicin or cisplatin – based HIPEC treatment have a 
significant higher load of bacterial ribosomal DNA (16s rDNA) (P=0.015, P=0.015) in 
their circulation compared to patients after HIPEC with oxaliplatin. Data are shown as 























































mitomycinC/doxorubicin (90min) cisplatin-based (90min) oxaliplatin (30min) 
Figure 4: Kinetics of WBC during an uncomplicated course
Figure 4A: Kinetics of white blood cells (WBC) levels in patients without infectious complications after CRS/HIPEC (n=107). After an initial 
increase, WBC decrease and remain in normal range after mitomcycinC/doxorubicin HIPEC (n=34). Figure 4B-4C: There is a significant 
secondary WBC increase in patients after platin-based HIPEC (n=38, cisplatin-based, p=0.011, n=35, oxaliplatin-based, p=0.027) between day 
4 and day 7. Data are shown as median and IQR.
